๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study

โœ Scribed by Jan Van Eys; Daisilee Berry; William Crist; Ed Doering; Donald Fernbach; Jeanette Pullen; Jon Shuster; And Moody Wharam


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
624 KB
Volume
63
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Four hundred thirty patients with high-risk acute lymphoid leukemia were entered on the acute leukemia in childhood protocol (AlinC 12) of the Pediatric Division of the Southwest Oncology Group (now the Pediatric Oncology Group) between 1976 and 1979. This study was a prospective randomized comparison of two regimens that had as their primary differences: (1) an intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; (2) a period of intravenous methotrexate before initiating maintenance; and (3) in the regimen that had those two additions, triple-drug chemoprophylaxis of the central nervous system (CNS) using methotrexate, hydrocortisone, and cytosine arabinoside as compared to cranial irradiation and intrathecal methotrexate. All patients received vincristine and prednisone induction, 6-mercaptopurine and methotrexate maintenance, and vincristine and prednisone pulse intensification. There was no significant difference in the rate of bone marrow relapse. However, overall diseasefree survival favored the arm with intensification and chemoprophylaxis because of a lesser incidence of extramedullary relapse. Thus, for treatment 1 versus treatment 3 the two-sided P values were for overall disease-free survival 0.16; bone marrow relapses 0.13; all CNS relapses 0.04; and all extramedullary disease relapses 0.013. It is concluded that intensification as delivered in this protocol protects against testicular relapse and that chemoprophylaxis is adequate prophylaxis against isolated CNS relapse.

Cancer 63:23-29, 1989.

N 1976, the Pediatric Division of the Southwest Oncology I Group, later reorganized as the Pediatric Oncology

Group, initiated a study, designated AlinC 12. Enrollment w,as from 1976 through 1979. The objective of this study w<as to compare, for patients with higher than average risk, two regimens that both were then accepted approaches to acute lymphocytic leukemia (ALL) treatment in children. One was patterned after St. Jude's regimen 04, designated as Total V and VII,' and the other after a University of Texas M. D. Anderson-generated regimen cded All-out #2.* The regimens had as their primary difference the following: (1) an intensification period after


๐Ÿ“œ SIMILAR VOLUMES


RAS gene mutations in childhood acute my
โœ Dr. Bert Vogelstein; Dr. Curt I. Civin; Antonette C. Preisinger; Jeffrey P. Kris ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 336 KB

Mutations at codon I 2, I 3, and 6 I of the HRAS, KRAS, and NRASgenes were evaluated in 99 cases of pediatric acute myeloid leukemia (AML) using oligonucleotide hybridization to polymerase chain reacted derived products. Twenty-four mutations were identified in the NRAS gene, I 3 in the KRAS gene, a

Treatment intensity and outcome for chil
โœ Jan van Eys; Daisilee Berry; William Crist; Ed Doering; Donald Fernbach; Jeanett ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 485 KB ๐Ÿ‘ 2 views

Four hundred thirty-four children, with good-risk acute lymphocytic leukemia (ALL), were assigned randomly to receive intensive or less intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses in such a way that patients on treatment 1 had their le